Published in Neuropsychiatr Dis Treat on January 22, 2015
A rating scale for depression. J Neurol Neurosurg Psychiatry (1960) 90.89
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry (2006) 14.15
The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry (2003) 13.60
Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry (2008) 4.98
Cross-national epidemiology of DSM-IV major depressive episode. BMC Med (2011) 4.52
Residual symptoms after partial remission: an important outcome in depression. Psychol Med (1995) 3.23
The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther (2000) 3.07
Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment. Arch Fam Med (1994) 3.02
Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry (2000) 2.70
Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med (2009) 1.91
Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry (2000) 1.89
Antidepressants in the treatment of neuropathic pain. Basic Clin Pharmacol Toxicol (2005) 1.58
The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatry (2004) 1.28
The outcome of physical symptoms with treatment of depression. J Gen Intern Med (2004) 1.24
Antidepressant agents for the treatment of chronic pain and depression. Pharmacotherapy (2007) 1.24
Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol (2007) 1.20
The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France. Curr Med Res Opin (2003) 1.20
Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report. Psychol Med (2009) 1.13
Sexual problems in healthy and depressed persons. Int Clin Psychopharmacol (1998) 1.11
Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int Clin Psychopharmacol (2010) 1.08
Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. Drug Alcohol Depend (2009) 1.06
Efficacy of noradrenergic and serotonergic antidepressants in chronic back pain: a preliminary concentration-controlled trial. J Clin Psychopharmacol (2007) 0.99
Do atypical features affect outcome in depressed outpatients treated with citalopram? Int J Neuropsychopharmacol (2009) 0.98
Mental health needs of Arab women. Health Care Women Int (2009) 0.97
Poor response to antidepressant medication of patients with depression accompanied by somatic symptomatology in the STAR*D Study. Psychiatry Res (2011) 0.92
Predicting the outcome of antidepressants and psychotherapy for depression: a qualitative, systematic review. Harv Rev Psychiatry (2008) 0.91
Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression. J Psychiatr Res (2008) 0.88
Frequency of treatment-emergent sexual dysfunction and treatment effectiveness during SSRI or duloxetine therapy: 8-week data from a 6-month observational study. Int J Psychiatry Clin Pract (2011) 0.85
Evaluation of reboxetine, a noradrenergic antidepressant, for the treatment of fibromyalgia and chronic low back pain. Psychosomatics (2005) 0.85
Stigma of Mental Illness-2: Non-compliance and Intervention. Mens Sana Monogr (2012) 0.84
Treatment-emergent sexual dysfunction with SSRIs and duloxetine: effectiveness and functional outcomes over a 6-month observational period. Int J Psychiatry Clin Pract (2011) 0.83
Predictors of 12-week remission in a nationwide cohort of people with depressive disorders: the CRESCEND study. Hum Psychopharmacol (2011) 0.83
Exploratory analysis of early treatment discontinuation and clinical outcomes of patients with attention-deficit/hyperactivity disorder. Asia Pac Psychiatry (2015) 0.79
Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review. Neuropsychiatr Dis Treat (2014) 0.77
Should Unexplained Painful Physical Symptoms be Considered within the Spectrum of Depressive Symptoms? Clin Pract Epidemiol Ment Health (2015) 0.77
Antidepressant medication treatment patterns in Asian patients with major depressive disorder. Patient Prefer Adherence (2015) 0.75
Diagnosis, treatment, and burden of illness among adults with attention-deficit/hyperactivity disorder in Europe. Pragmat Obs Res (2014) 0.75
Health-related quality of life in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in a naturalistic outpatient setting. Patient Prefer Adherence (2015) 0.75
Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia. Neuropsychiatr Dis Treat (2016) 0.75
Recovery in patients with major depressive disorder (MDD): results of a 6-month, multinational, observational study. Patient Prefer Adherence (2017) 0.75
Real-world Effectiveness of Antipsychotics for the Treatment of Negative Symptoms in Patients with Schizophrenia with Predominantly Negative Symptoms. Pharmacopsychiatry (2017) 0.75
Lost in transition: A review of the unmet need of patients with attention deficit/hyperactivity disorder transitioning to adulthood. Asia Pac Psychiatry (2016) 0.75